You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 22, 2025

Drugs in MeSH Category Antimanic Agents


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm Inds CARBAMAZEPINE carbamazepine TABLET, CHEWABLE;ORAL 075687-002 Jul 29, 2002 RX No Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Taro TERIL carbamazepine SUSPENSION;ORAL 076729-001 Sep 20, 2004 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Lundbeck Pharms Llc CARNEXIV carbamazepine SOLUTION;INTRAVENOUS 206030-001 Oct 7, 2016 DISCN Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Yichang Humanwell CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 219072-002 Jan 16, 2025 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Osmotica Pharm Us CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 215664-002 Oct 22, 2024 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Antimanic Agents Market Analysis and Financial Projection

The market dynamics and patent landscape for antimanic agents – classified under NLM's MeSH code D27.505.696.277.950.025 – reveal a complex interplay of clinical demand, pharmaceutical innovation, and intellectual property strategies. These drugs, primarily used to manage bipolar disorder, exist within the broader $17B-$29B antipsychotic therapeutics market projected to grow at 5.4%-6.5% CAGR through 2032[2][6][9][10].

Market Dynamics

Growth Drivers:

  • Epidemiological Burden: 45 million global bipolar disorder cases create sustained demand, with WHO reporting 1-2% lifetime prevalence[14].
  • Cost-Effectiveness Battles: Monthly treatment costs range from $16 (lithium) to $153 (olanzapine), driving variable adoption patterns[14].
  • Pipeline Innovation: Phase III trials of novel agents like lumateperone show 52% remission rates in bipolar depression versus 35% placebo[14].
  • Regional Shifts: North America holds 45-61% market share[9][10], while APAC anticipates 7.7% CAGR through 2032 due to healthcare infrastructure growth[10].

Competitive Landscape:

  • First-Line Agents: Haloperidol (-0.56 SMD), risperidone (-0.50), and olanzapine (-0.43) dominate efficacy profiles but face dropout rates up to 28%[5].
  • Emerging Models: Psychiatry Consortium's 2019 initiative unites 14 pharma players in bipolar disorder R&D, accelerating translational research[14].

Patent Landscape

Key Protection Strategies:

  • Patent Clustering: Top antipsychotics average 74 granted patents, with 66% filed post-FDA approval to extend exclusivity[11]. Example: Otsuka's delamanid holds 28 patent families across manufacturing and formulation[7].
  • Biosimilar Barriers: Janssen's Stelara® demonstrates defensive patenting with 5+ patents challenged in recent biosimilar litigation[8].
  • Novel Mechanism IP: EP2218450A1 covers memantine's repurposing for treatment-resistant bipolar disorder via NMDA modulation[12].

Market Impact:

  • Exclusivity Periods: Innovators maintain 10-17 year market control through SPCs and pediatric extensions – bevacizumab retained EU protection until 2022[3].
  • AI-Driven Analysis: Machine learning identifies white spaces in 78% of antipsychotic patent portfolios, reducing prior art search time by 40%[13][15].

Strategic Considerations

Factor Impact Data Source
Generic Entry Delay $167B branded sales post-patent expiry for 3 top drugs[11] I-MAK Analysis
Telemedicine Adoption 32% increase in antipsychotic Rx via telehealth during COVID[10] Fortune Business Insights
AI Patent Mapping 140% increase in predictive accuracy for litigation risks[15] PowerPatent Analytics

The convergence of mental health prioritization and IP complexity creates both opportunities and challenges. While 68% of industry leaders plan increased antimanic R&D spend[9], 42% cite patent thickets as the primary barrier to biosimilar entry[11]. This landscape demands integrated strategies combining clinical efficacy data, cost containment measures, and proactive IP analytics.

References

  1. https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D27)
  2. https://www.imarcgroup.com/antipsychotic-drugs-market
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC7188399/
  4. http://etheses.lse.ac.uk/973/1/Naci_Generating_Comparative_Data_Clinical_Benefits_Harms_Statins.pdf
  5. https://pubmed.ncbi.nlm.nih.gov/21851976/
  6. https://www.globenewswire.com/news-release/2024/10/28/2970176/0/en/Global-Antipsychotic-Drugs-Market-to-Reach-USD-29-23-Billion-by-2032-Driven-by-Rising-Mental-Health-Awareness-and-Drug-Innovation-SNS-Insider.html
  7. https://unitaid.org/uploads/OPC-67683_Patent_Landscape.pdf
  8. https://www.biosimilarsip.com/wp-content/uploads/sites/768/2023/05/First-Amended-Complaint_3.7.2023.pdf
  9. https://www.fortunebusinessinsights.com/industry-reports/antipsychotic-drugs-market-101390
  10. https://market.us/report/antipsychotic-drugs-market/
  11. https://www.i-mak.org/wp-content/uploads/2022/09/Overpatented-Overpriced-2022-FINAL.pdf
  12. https://patents.google.com/patent/EP2218450A1/en
  13. https://powerpatent.com/blog/ais-contribution-to-patent-landscape-mapping/
  14. https://www.coherentmarketinsights.com/market-insight/antimania-drugs-market-4143/market-size-and-trends
  15. https://patentpc.com/blog/ip-landscape-analysis

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.